Anixa Biosciences (NASDAQ:ANIX) Upgraded to Hold at Wall Street Zen

Key Points

• Wall Street Zen upgraded Anixa Biosciences from a "sell" to a "hold," and the stock has an average MarketBeat consensus rating of Hold with a $9.00 consensus price target (analyst mix: 3 Buys, 1 Hold, 1 Sell).
• The shares are trading around $2.85 with a market cap of about $95 million, a negative trailing EPS (company forecast ~-0.41 EPS for the year), and a 12-month range of $2.33–$5.46.
• Insider activity and institutional buying have increased recently: a director purchased 10,000 shares at $3.04, insiders own 26.4% of the stock, and institutional investors hold roughly 29% after several new or expanded stakes.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) was upgraded by analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued on Saturday.

Several other brokerages also recently weighed in on ANIX. D. Boral Capital restated a "buy" rating and set a $10.00 target price on shares of Anixa Biosciences in a research note on Wednesday, February 4th. Zacks Research lowered Anixa Biosciences from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, November 18th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Anixa Biosciences in a report on Monday, December 29th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Anixa Biosciences currently has an average rating of "Hold" and a consensus price target of $9.00.

Anixa Biosciences Trading Down 1.4%

Shares of ANIX stock opened at $2.85 on Friday. The company has a market cap of $95.13 million, a price-to-earnings ratio of -8.14 and a beta of 0.48. Anixa Biosciences has a 12-month low of $2.33 and a 12-month high of $5.46. The stock has a 50 day simple moving average of $3.05 and a 200-day simple moving average of $3.55.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last posted its earnings results on Monday, January 12th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09). On average, equities analysts forecast that Anixa Biosciences will post -0.41 earnings per share for the current fiscal year.

Insider Activity

In other Anixa Biosciences news, Director Arnold M. Baskies acquired 10,000 shares of the company's stock in a transaction that occurred on Wednesday, January 28th. The shares were acquired at an average price of $3.04 per share, with a total value of $30,400.00. Following the purchase, the director owned 135,000 shares of the company's stock, valued at $410,400. This represents a 8.00% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 26.40% of the stock is owned by company insiders.

Institutional Trading of Anixa Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of ANIX. 683 Capital Management LLC acquired a new position in shares of Anixa Biosciences in the fourth quarter valued at $355,000. ExodusPoint Capital Management LP acquired a new stake in Anixa Biosciences in the fourth quarter valued at about $293,000. Susquehanna International Group LLP increased its holdings in shares of Anixa Biosciences by 378.4% during the third quarter. Susquehanna International Group LLP now owns 80,387 shares of the company's stock worth $265,000 after buying an additional 63,584 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences during the 4th quarter valued at $161,000. Finally, State Street Corp grew its position in Anixa Biosciences by 32.0% during the 4th quarter. State Street Corp now owns 159,040 shares of the company's stock worth $496,000 after acquiring an additional 38,540 shares during the last quarter. Institutional investors and hedge funds own 29.13% of the company's stock.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.